Search research articles
Contact Us
Filters
Showing results (1341-1350 of 1,433) with videos related to
Page
of 144
Sort By:
NPJ Breast Cancer
|
February 5, 2025
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
Luca Mastrantoni, Giovanna Garufi, Giulia Giordano, et al.
Nature Medicine
|
January 21, 2025
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Sherene Loi, Roberto Salgado, Giuseppe Curigliano, et al.
Cancer Treatment Reviews
|
August 29, 2024
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review
Alberto Zambelli, Laura Cortesi, Mariangela Gaudio, et al.
Journal of the National Cancer Institute
|
December 28, 2022
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, et al.
Cancers
|
July 18, 2020
<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
Gaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 12, 2019
HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa
K Peris, A Lo Schiavo, G Fabbrocini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Biomedical Reports
|
April 7, 2022
Clinical characteristics and predictors of death among hospitalized patients infected with SARS-CoV-2 in Sicily, Italy: A retrospective observational study
Federica Cosentino, Vittoria Moscatt, Andrea Marino, et al.
The New England Journal of Medicine
|
June 2, 2025
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Mario Campone, Michelino De Laurentiis, Komal Jhaveri, et al.
Page
of 144
Search research articles
Search
Showing results (1341-1350 of 1,433) with videos related to
Sort By:
Page
of 144
NPJ Breast Cancer
|
February 5, 2025
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
Luca Mastrantoni, Giovanna Garufi, Giulia Giordano, et al.
Nature Medicine
|
January 21, 2025
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Sherene Loi, Roberto Salgado, Giuseppe Curigliano, et al.
Cancer Treatment Reviews
|
August 29, 2024
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review
Alberto Zambelli, Laura Cortesi, Mariangela Gaudio, et al.
Journal of the National Cancer Institute
|
December 28, 2022
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, et al.
Cancers
|
July 18, 2020
<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
Gaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 12, 2019
HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa
K Peris, A Lo Schiavo, G Fabbrocini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Biomedical Reports
|
April 7, 2022
Clinical characteristics and predictors of death among hospitalized patients infected with SARS-CoV-2 in Sicily, Italy: A retrospective observational study
Federica Cosentino, Vittoria Moscatt, Andrea Marino, et al.
The New England Journal of Medicine
|
June 2, 2025
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Mario Campone, Michelino De Laurentiis, Komal Jhaveri, et al.
Page
of 144